Patents
Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210)
08/2002
08/15/2002WO2002063010A2 Method of producing recombinant antibodies against tumors
08/15/2002WO2002063009A2 Lp mammalian proteins; related reagents
08/15/2002WO2002063008A2 Intracellular signaling molecules
08/15/2002WO2002063007A2 TIMM8b-RELATED PROTEIN
08/15/2002WO2002063006A2 Receptors and membrane-associated proteins
08/15/2002WO2002063005A2 Lipid-associated molecules
08/15/2002WO2002063004A2 G-protein coupled receptors
08/15/2002WO2002063003A2 Platlet glycoprotein ib alpha fusion polypeptides and methods of use thereof
08/15/2002WO2002063002A2 Novel human transporter protein and polynucleotides encoding the same
08/15/2002WO2002063001A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
08/15/2002WO2002063000A2 Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same
08/15/2002WO2002062999A2 Proteins and nucleic acids encoding same
08/15/2002WO2002062998A1 Novel protein and dna thereof
08/15/2002WO2002062997A1 Novel protein and use thereof
08/15/2002WO2002062996A1 Novel physiologically active peptide and use thereof
08/15/2002WO2002062995A2 Human dorsal root receptor-like g protein-coupled receptor
08/15/2002WO2002062994A1 Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals
08/15/2002WO2002062992A1 Method of eukaryotic expression cloning of disease associated molecules
08/15/2002WO2002062991A1 Insertional mutagenesis technique
08/15/2002WO2002062989A2 Methods of light activated release 0f ligands from endosomes
08/15/2002WO2002062988A2 Recombination method
08/15/2002WO2002062987A2 Method for producing homogeneous nucleic acid multimers for use in pharmaceutical compositions
08/15/2002WO2002062986A2 Replicative in vivo gene targeting
08/15/2002WO2002062979A2 Enzyme
08/15/2002WO2002062977A2 Human phospholipase b-like polypeptide and uses thereof
08/15/2002WO2002062976A2 Serine proteases
08/15/2002WO2002062973A2 Lipase variants
08/15/2002WO2002062972A2 Hybridoma cell line g250 and its use for producing monoclonal antibodies
08/15/2002WO2002062967A2 Multipotent o-2a progenitors from the neurohypophysis
08/15/2002WO2002062965A2 Method for identifying intercellular protein factors
08/15/2002WO2002062964A2 Ap1 amine oxidase variants
08/15/2002WO2002062959A2 Hepatitis b virus treatment
08/15/2002WO2002062957A2 Ter sites and ter binding proteins
08/15/2002WO2002062955A2 Dendritic enriched secreted lymphocyte activation molecule
08/15/2002WO2002062954A2 Antisense modulation of casein kinase 2-beta expression
08/15/2002WO2002062953A2 Human hyperpolarization-activated cyclic nucleotide-gated cation channel hcn1
08/15/2002WO2002062952A2 Non-cytotoxic pap mutants
08/15/2002WO2002062951A2 Antisense modulation of casein kinase 2-alpha prime expression
08/15/2002WO2002062949A2 Aptamer-mediated regulation of gene expression
08/15/2002WO2002062945A2 Compositions and methods relating to lung specific genes and proteins
08/15/2002WO2002062944A2 Novel physiologically active peptide and use thereof
08/15/2002WO2002062943A2 Use of oligonucleotides for improving plasmid transfection in cells, transfection method and kit
08/15/2002WO2002062851A1 Conformationally abnormal forms of tau proteins and specific antibodies thereto
08/15/2002WO2002062850A2 Hybrid antibodies and uses thereof
08/15/2002WO2002062849A2 Isolated human ras-like proteins, nucleic acid molecules encoding them, and uses thereof
08/15/2002WO2002062848A2 Regulation of cc chemokine receptor 3 (ccr3) expression
08/15/2002WO2002062847A2 Superficial zone protein and methods of making and using same
08/15/2002WO2002062846A2 Method and apparatus for the production of antigens and uses thereof
08/15/2002WO2002062843A2 Modified erythropoietin (epo) with reduced immunogenicity
08/15/2002WO2002062842A1 Modified keratinocyte growth factor (kgf) with reduced immunogenicity
08/15/2002WO2002062841A2 Secreted proteins
08/15/2002WO2002062840A1 INTERFERON-α INDUCED GENE
08/15/2002WO2002062839A2 Markers of unstable atherosclerotic plaques
08/15/2002WO2002062834A2 Mixture of peptides originating from a nef protein and applications thereof
08/15/2002WO2002062833A2 Modified leptin with reduced immunogenicity
08/15/2002WO2002062832A2 Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
08/15/2002WO2002062823A2 Peptides for facilitating composite receptor expression and translocation of macromolecules
08/15/2002WO2002062822A2 Methods of identifying regulator molecules
08/15/2002WO2002062821A2 Peptide or protein microassay method and apparatus
08/15/2002WO2002062818A2 Antisense modulation of casein kinase 2-alpha expression
08/15/2002WO2002062395A2 A method and system for introducing a gene into a human stem cell
08/15/2002WO2002062381A1 Baculovirus vector vaccine
08/15/2002WO2002062380A2 Chlamydia vaccine composition
08/15/2002WO2002062379A2 Clostridium difficile vaccine
08/15/2002WO2002062378A2 Hyperblebbing bacterial strains and use thereof for production of vaccines
08/15/2002WO2002062375A1 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
08/15/2002WO2002062298A2 Pro-apoptotic bacterial vaccines to enhance cellular immune responses
08/15/2002WO2002062297A2 Methods and compositions for modulating gluconeogenesis using pgc-1
08/15/2002WO2002062296A2 Methods and compositions useful for stimulating an immune response
08/15/2002WO2002062205A2 Methods for diagnosing and treating heart disease
08/15/2002WO2002062204A2 Methods for diagnosing and treating heart disease
08/15/2002WO2002062201A2 Rare event detection system
08/15/2002WO2002062197A2 Markers for disease susceptibility and targets for therapy
08/15/2002WO2002062144A2 Method for controlling harmful organisms in the culture of useful plants
08/15/2002WO2002062135A2 Scce modified transgenic mammals and their use as models of human disease
08/15/2002WO2002062134A1 Human sphingosine-1-phosphate phosphatase
08/15/2002WO2002062131A2 Method of cloning transgenic mammalian animals using pseudonuclei
08/15/2002WO2002051871A3 Anti-cd28 antibody
08/15/2002WO2002051858A3 Antisense modulation of chk2 expression
08/15/2002WO2002051800A3 Sulphur-containing amphiphilic agents for the transfer of biologically active molecules into cells
08/15/2002WO2002050101A8 Retinoblastoma-binding protein
08/15/2002WO2002046404A9 Schizophrenia-related voltage-gated ion channel gene and protein
08/15/2002WO2002046363A3 Improved methods for gene expression monitoring on electronic microarrays
08/15/2002WO2002032937A3 Neuromedin u delta
08/15/2002WO2002032419A3 Methods for modulating bladder function
08/15/2002WO2002026968A9 Antisense iap nucleic acids and uses thereof
08/15/2002WO2002026376A3 High density arrays
08/15/2002WO2002024932A3 Expression vectors containing hybrid ubiquitin promoters
08/15/2002WO2002019966A3 Cardiac arrhythmia treatment methods
08/15/2002WO2002018554A3 Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof
08/15/2002WO2002016590A3 Methods and compositions for increasing protein yield from a cell culture
08/15/2002WO2002013763A3 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
08/15/2002WO2002009510A3 Methods of selecting and cloning animals
08/15/2002WO2002006469A3 Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids
08/15/2002WO2002006303A3 Dna vaccines encoding hiv accessory proteins
08/15/2002WO2002002794A3 Integrated microarray devices
08/15/2002WO2002002621A3 Mammalian secreted proteins
08/15/2002WO2002000900A3 Binary vectors for improved transformation of plant systems
08/15/2002WO2002000897A3 Novel chimeric promoters
08/15/2002WO2002000884A3 Nucleotide sequence of influenza a/udorn/72 (h3n2) genome